Asset Details
Do you wish to reserve the book?
Plant-produced Bluetongue chimaeric VLP vaccine candidates elicit serotype-specific immunity in sheep
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Plant-produced Bluetongue chimaeric VLP vaccine candidates elicit serotype-specific immunity in sheep
Do you wish to request the book?
Plant-produced Bluetongue chimaeric VLP vaccine candidates elicit serotype-specific immunity in sheep
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Plant-produced Bluetongue chimaeric VLP vaccine candidates elicit serotype-specific immunity in sheep
2019
Overview
Bluetongue (BT) is a hemorrhagic non-contagious, biting midge-transmitted disease of wild and domestic ruminants that is caused by bluetongue virus (BTV). Annual vaccination plays a pivotal role in BT disease control in endemic regions. Due to safety concerns of the current BTV multivalent live attenuated vaccine (LAV), a safe efficacious new generation subunit vaccine such as a plant-produced BT virus-like particle (VLP) vaccine is imperative. Previously, homogenous BTV serotype 8 (BTV-8) VLPs were successfully produced in Nicotiana benthamiana plants and provided protective immunity in sheep. In this study, combinations of BTV capsid proteins from more than one serotype were expressed and assembled to form chimaeric BTV-3 and BTV-4 VLPs in N. benthamiana plants. The assembled homogenous BTV-8, as well as chimaeric BTV-3 and chimaeric BTV-4 VLP serotypes, were confirmed by SDS-PAGE, Transmission Electron microscopy (TEM) and protein confirmation using liquid chromatography-mass spectrometry (LC-MS/MS) based peptide sequencing. As VP2 is the major determinant eliciting protective immunity, the percentage coverage and number of unique VP2 peptides detected in assembled chimaeric BT VLPs were used as a guide to assemble the most appropriate chimaeric combinations. Both plant-produced chimaeric BTV-3 and BTV-4 VLPs were able to induce long-lasting serotype-specific neutralizing antibodies equivalent to the monovalent LAV controls. Antibody levels remained high to the end of the trial. Combinations of homogenous and chimaeric BT VLPs have great potential as a safe, effective multivalent vaccine with the ability to distinguish between vaccinated and infected individuals (DIVA) due to the absence of non-structural proteins.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Animals
/ Antibodies, Neutralizing - blood
/ Antigens
/ Biting
/ Bluetongue - prevention & control
/ Bluetongue virus - immunology
/ Capsid Proteins - immunology
/ Chimaeric BT virus-like particles
/ Cloning
/ Coverage
/ Genes
/ Genomes
/ Immunity
/ Peptides
/ polyacrylamide gel electrophoresis
/ Proteins
/ Sheep
/ Transmission electron microscopy
/ Vaccine
/ Vaccines
/ Vaccines, Attenuated - immunology
/ Vaccines, Virus-Like Particle - immunology
/ viral nonstructural proteins
/ virus-like particle vaccines
/ Viruses
